Development of a quantitative fluorescence lateral flow immunoassay (LFIA) prototype for point-of-need detection of anti-Müllerian hormone

Accelerated Development of a COVID-19 Lateral Flow Test in an Academic Setting: Lessons Learned

“…The COVID-19 pandemic emphasized the urgent need for user-centered, reliable, and cost-effective point-of-care diagnostics that can be broadly deployed, ideally for self-testing at home. The Willson laboratory at the University of Houston focuses on the development of sensitive, translatable analytical methods for point-of-care diagnostics, especially tests using novel reporter technologies readable by a smartphone, and had developed an early proof-of-principle of novel LFA technologies potentially applicable to this need. − …”